Asia Regenerative Medicine
PrivateLast Round
Series A
Oct 30, 2025
Company Overview
Asia Regenerative Medicine is a biotechnology company that develops stem cell and tissue engineering technologies focused on addressing kidney disease and other organ-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asia Regenerative Medicine Comparables
Compare Asia Regenerative Medicine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rege Nephro Co., Ltd. | 82% | |
| Trestle Biotherapeutics | 77% | |
| Help Therapeutics | 71% |
Asia Regenerative Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 30, 2025 | ||||
| VC Round | Jun 1, 2023 | ||||
| VC Round | Jan 1, 2023 | ||||
| Pre Seed | Aug 17, 2021 |
Asia Regenerative Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kexi Capital | VC Round |
| DM Capital | VC Round, Series A |
| Xiamen High-tech Investment | VC Round |
| Beijing Zhenghe Zhengxin Investment Management | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
Monthly visitors increased 445% MoM.
- May 4, 2025
Monthly visitors grew 92% MoM.
Asia Regenerative Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Asia Regenerative Medicine's valuation, stock price, and market status.
Is Asia Regenerative Medicine a public or private company?
Asia Regenerative Medicine is a private company.
What is the current stock price of Asia Regenerative Medicine?
Asia Regenerative Medicine is a private company with no public stock price. No recent secondary market data is available.
How much is Asia Regenerative Medicine worth (valuation)?
Valuation information for Asia Regenerative Medicine is not publicly available.
Can I buy Asia Regenerative Medicine stock?
Asia Regenerative Medicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Asia Regenerative Medicine's last funding round?
Asia Regenerative Medicine's most recent funding round was Series A on October 30, 2025.
Who are the main investors in Asia Regenerative Medicine?
Key investors in Asia Regenerative Medicine include Kexi Capital, DM Capital, Xiamen High-tech Investment, Beijing Zhenghe Zhengxin Investment Management.
Will Asia Regenerative Medicine IPO soon?
No public IPO plans have been announced for Asia Regenerative Medicine.
How can I track Asia Regenerative Medicine secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Asia Regenerative Medicine's secondary market activity and sign up for updates.